Nucleome Therapeutics Appoints Dr. Phil Boyd as Chief Financial Officer


Nucleoma therapy

Nucleome Therapeutic appointed Doctor Phil Boyd as Chief Financial Officer

Phil brought more than 20 years of first class financial experience in the life sciences industry

OOxford, United Kingdom, 21 April 2022 – Nucleome Therapeutics (“Nucleome” or “the Company”), a biotechnology company using breakthrough technologies to decode the dark matter of the human genome to discover precision medicines, is pleased to announce the appointment of Dr. Phil Boyd to CFO position at immediate effect.

“Phil is a highly accomplished CFO with extensive experience and an impressive track record in the biotech industry; I am delighted to welcome him to our management team,” commented Dr. Danuta Jeziorska, CEO and Founder of Nucleome. “His vast experience in finance and operations will be instrumental in our strategic growth as we continue to decode the dark genome and begin biological validation of our first drug targets with the ambition to build discovery programs for the treatment of diseases. autoimmune.

Phil, who is a strategic finance professional and management accountant with over 20 years of experience in the biotech sector, will join on a part-time basis. He will retain his role as chief financial officer for private life sciences company Enterprise Therapeutics, and he will remain as a non-executive director and chairman of the audit committee for UK BioCentre.

Previous companies where Phil served as CFO include Caldan Therapeutics, Epsilogen, Syntaxin from 2007 through several funding rounds until its acquisition by Ipsen in 2013, Tiziana Lifesciences plc when it went public in April 2014 and Oxford BioDynamics in preparation for its IPO in December 2016.

Phil has also served as Chairman of the Finance Committee of the BioIndustry Association (BIA) and Non-Executive Director of OBN (UK). He holds a BSc in Biotechnology and a PhD in Genetics from the University of Leeds and is a Fellow of the Royal Society of Biology and a Visiting Fellow at Durham University Business School.

Doctor Phil Boyd, Chief Financial Officer of Nucleomementioned: “I am delighted to have the opportunity to join Nucleome. My first scientific training was in genetics, and it is clear that Nucleome has real potential to be a game-changer in drug discovery. The company’s breakthrough technology offers us the unique ability to unlock the largely unexplored dark genome to discover precision medicines and understand complex diseases It is rare to come across a company with such compelling science, such growth potential and a solid platform to fuel growth future.”

– To finish –

On Nucleome Therapeutic
Nucleome Therapeutics decodes the dark matter of the human genome to discover new ways to treat disease. The dark genome contains more than 90% of disease-related genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. We have the unique ability to link these variants to gene function and map disease pathways. Our cell type-specific platform creates high-resolution 3D genome structure maps and enables functional validation of large-scale variants in primary cell types. This allows us to discover and develop new, better and safer medicines. The company initially focuses on lymphocytes and related autoimmune diseases. Our ambition is to build a solid pipeline of medicinal actives, with the corresponding biomarkers. Nucleome Therapeutics was founded by leading gene regulation experts at the University of Oxford and backed by investment from Oxford Sciences Innovation. For more information, visit

For more information please contact:

Nucleome Therapeutic
Dr. Danuta Jeziorska, CEO and Founder
[email protected]

Advice Strategic Communications
Mary-Jane Elliott/ Sukaina Virji/ Lindsey Neville
[email protected]


About Author

Comments are closed.